Clinical Trials
Tiziana Life Sciences completes clinical trial of nasally administered Foralumab to treat COVID-19 in Brazil
Tiziana Life Sciences announced the completion of its clinical study in Brazil investigating nasally administered Foralumab, its proprietary human monoclonal antibody, either alone or in combination with orally administered dexamethasone in COVID-19 patients.
The clinical study was completed in collaboration...
Clinical Trials
AbbVie, Boehringers Skyrizi yields positive results in Phase III psoriatic arthritis trials
AbbVie reported data from a pair of Phase III studies showing that Skyrizi (risankizumab) led to significantly more psoriatic arthritis patients achieving the primary endpoint of at least 20% improvement on American College of Rheumatology (ACR20) criteria than placebo...
Clinical Trials
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Vir Biotechnology, Inc. announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to...
Clinical Trials
New Clinical Research Accreditation Launches to Meet Industry Demands
GCSA launched with a commitment to increase clinical research and trial capacity and quality in the UK as well as Globally. This will be achieved through the introduction of an industry leading standard for improving, maintaining and accrediting clinical...
Clinical Trials
Covid-19: Russia’s Sputnik V vaccine confirms 91.4% efficacy
Russia’s Sputnik V vaccine has demonstrated an efficacy of over 90 percent, according to the Gamaleya Center and the Russian Direct Investment Fund.
“Evaluation of efficacy was carried out among volunteers 21 days after receiving the first dose of the...
Clinical Trials
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, in markets accepting the CE Mark. Roche has also filed for Emergency Use...
Clinical Trials
Sanofi, GSK COVID-19 vaccine rollout delayed on low immune response in older adults
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















